| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $999,997 ) |
| | 2025 | 2025 | CURZA INC | 650 S KOMAS DR STE 202 | SALT LAKE CITY | UT | 84108-1241 | SALT LAKE | USA | R44AI184155 | A new class of antibiotic to address Antimicrobial Resistance | 001 | 2 | NIH | 4/24/2025 | $999,997 |
| | 2025 | 2024 | CURZA INC | 650 S KOMAS DR STE 202 | SALT LAKE CITY | UT | 84108-1241 | SALT LAKE | USA | R44AI184155 | A new class of antibiotic to address Antimicrobial Resistance | 000 | 1 | NIH | 4/18/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $2,999,998 ) |
| | 2024 | 2024 | CURZA INC | 650 S KOMAS DR STE 202 | SALT LAKE CITY | UT | 84108-1241 | SALT LAKE | USA | R44AI184155 | A new class of antibiotic to address Antimicrobial Resistance | 000 | 1 | NIH | 4/30/2024 | $999,998 |
| | 2024 | 2024 | CURZA INC | 650 S KOMAS DR STE 202 | SALT LAKE CITY | UT | 84108-1241 | SALT LAKE | USA | R44AI170297 | A New Class of Broad-Spectrum Antibacterial Agents to Treat Multi-Drug Resistant Pathogens | 000 | 2 | NIH | 6/11/2024 | $1,000,000 |
| | 2024 | 2024 | CURZA INC | 650 S KOMAS DR STE 202 | SALT LAKE CITY | UT | 84108-1241 | SALT LAKE | USA | R44AI186898 | New oral antibiotics focused on treating MDR Gram-negative infections | 000 | 1 | NIH | 7/9/2024 | $1,000,000 |
| | 2024 | 2022 | CURZA INC | 650 S KOMAS DR STE 202 | SALT LAKE CITY | UT | 84108-1241 | SALT LAKE | USA | R44AI152665 | A new class of broad-spectrum antibacterials for treating MDR infections | 000 | 3 | NIH | 2/20/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $966,962 ) |
| | 2023 | 2023 | CURZA INC | 650 S KOMAS DR STE 202 | SALT LAKE CITY | UT | 84108-1241 | SALT LAKE | USA | R44AI170297 | A New Class of Broad-Spectrum Antibacterial Agents to Treat Multi-Drug Resistant Pathogens | 000 | 1 | NIH | 7/21/2023 | $1,000,000 |
| | 2023 | 2023 | CURZA INC | 650 S KOMAS DR STE 202 | SALT LAKE CITY | UT | 84108-1241 | SALT LAKE | USA | R44AI170297 | A New Class of Broad-Spectrum Antibacterial Agents to Treat Multi-Drug Resistant Pathogens | 001 | 1 | NIH | 8/15/2023 | $0 |
| | 2023 | 2021 | CURZA GLOBAL LLC | 650 S KOMAS DR | SALT LAKE CITY | UT | 84108-1215 | SALT LAKE | USA | R01AI132304 | Broad spectrum antibacterials selectively targeting an un-drugged site on the ribosome | 000 | 5 | NIH | 4/29/2023 | $0 |
| | 2023 | 2021 | CURZA INC | 650 S KOMAS DR STE 202 | SALT LAKE CITY | UT | 84108-1241 | SALT LAKE | USA | R01AI132304 | Broad spectrum antibacterials selectively targeting an un-drugged site on the ribosome | 001 | 5 | NIH | 9/22/2023 | -$707 |
| | 2023 | 2017 | CURZA INC | 650 S KOMAS DR STE 202 | SALT LAKE CITY | UT | 84108-1241 | SALT LAKE | USA | R43AI124821 | Natural product-inspired antibacterials with unique ribosomal binding | 000 | 2 | NIH | 10/1/2022 | -$32,331 |
|
| Issue Date FY: 2022 ( Subtotal = $1,000,000 ) |
| | 2022 | 2022 | CURZA GLOBAL LLC | 650 S KOMAS DR STE 202 | SALT LAKE CITY | UT | 84108-1241 | SALT LAKE | USA | R44AI152665 | A new class of broad-spectrum antibacterials for treating MDR infections | 000 | 3 | NIH | 4/15/2022 | $1,000,000 |
|
| Issue Date FY: 2021 ( Subtotal = $2,953,267 ) |
| | 2021 | 2021 | CURZA GLOBAL LLC | 650 S KOMAS DR STE 202 | SALT LAKE CITY | UT | 84108-1241 | SALT LAKE | USA | R01AI132304 | Broad spectrum antibacterials selectively targeting an un-drugged site on the ribosome | 002 | 5 | NIH | 7/23/2021 | $1,045,564 |
| | 2021 | 2021 | CURZA GLOBAL LLC | 650 S KOMAS DR STE 202 | SALT LAKE CITY | UT | 84108-1241 | SALT LAKE | USA | R44AI152665 | A new class of broad-spectrum antibacterials for treating MDR infections | 000 | 2 | NIH | 4/2/2021 | $1,000,000 |
| | 2021 | 2020 | CURZA GLOBAL LLC | 650 S KOMAS DR STE 202 | SALT LAKE CITY | UT | 84108-1241 | SALT LAKE | USA | R01AI132304 | Broad spectrum antibacterials selectively targeting an un-drugged site on the ribosome | 001 | 4 | NIH | 6/25/2021 | $451,971 |
| | 2021 | 2019 | CURZA GLOBAL LLC | 650 S KOMAS DR STE 202 | SALT LAKE CITY | UT | 84108-1241 | SALT LAKE | USA | R01AI132304 | Broad spectrum antibacterials selectively targeting an un-drugged site on the ribosome | 000 | 3 | NIH | 6/25/2021 | $455,732 |
|
| Issue Date FY: 2020 ( Subtotal = $1,741,700 ) |
| | 2020 | 2020 | CURZA GLOBAL LLC | 650 S KOMAS DR STE 202 | SALT LAKE CITY | UT | 84108-1241 | SALT LAKE | USA | R01AI132304 | Broad spectrum antibacterials selectively targeting an un-drugged site on the ribosome | 000 | 4 | NIH | 6/3/2020 | $741,700 |
| | 2020 | 2020 | CURZA GLOBAL LLC | 650 S KOMAS DR STE 202 | SALT LAKE CITY | UT | 84108-1241 | SALT LAKE | USA | R44AI152665 | A new class of broad-spectrum antibacterials for treating MDR infections | 000 | 1 | NIH | 4/24/2020 | $1,000,000 |
| | 2020 | 2020 | CURZA GLOBAL LLC | 650 S KOMAS DR STE 202 | SALT LAKE CITY | UT | 84108-1241 | SALT LAKE | USA | R44AI152665 | A new class of broad-spectrum antibacterials for treating MDR infections | 001 | 1 | NIH | 6/29/2020 | $1,000,000 |
| | 2020 | 2020 | CURZA GLOBAL LLC | 650 S KOMAS DR STE 202 | SALT LAKE CITY | UT | 84108-1241 | SALT LAKE | USA | R44AI152665 | A new class of broad-spectrum antibacterials for treating MDR infections | 001 | 1 | NIH | 6/29/2020 | -$1,000,000 |
|
| Issue Date FY: 2019 ( Subtotal = $745,853 ) |
| | 2019 | 2019 | CURZA GLOBAL LLC | 5152 EDGEWOOD DR STE 375 | PROVO | UT | 84604-5596 | UTAH | USA | R01AI132304 | Broad spectrum antibacterials selectively targeting an un-drugged site on the ribosome | 000 | 3 | NIH | 6/14/2019 | $750,834 |
| | 2019 | 2017 | CURZA GLOBAL LLC | 5152 EDGEWOOD DR STE 375 | PROVO | UT | 84604-5596 | UTAH | USA | R43AI124821 | Natural product-inspired antibacterials with unique ribosomal binding | 000 | 2 | NIH | 2/8/2019 | -$4,981 |
|
| Issue Date FY: 2018 ( Subtotal = $766,731 ) |
| | 2018 | 2018 | CURZA GLOBAL LLC | 5152 EDGEWOOD DR STE 375 | PROVO | UT | 84604-5596 | UTAH | USA | R01AI132304 | Broad spectrum antibacterials selectively targeting an un-drugged site on the ribosome | 000 | 2 | NIH | 6/26/2018 | $766,731 |
|
| Issue Date FY: 2017 ( Subtotal = $1,165,759 ) |
| | 2017 | 2017 | CURZA GLOBAL LLC | 5152 EDGEWOOD DR STE 375 | PROVO | UT | 84604-5596 | UTAH | USA | R43AI124821 | Natural product-inspired antibacterials with unique ribosomal binding | 001 | 2 | NIH | 8/25/2017 | -$298,770 |
| | 2017 | 2017 | CURZA GLOBAL LLC | 5152 EDGEWOOD DR STE 375 | PROVO | UT | 84604-5596 | UTAH | USA | R01AI132304 | Broad spectrum antibacterials selectively targeting an un-drugged site on the ribosome | 000 | 1 | NIH | 6/20/2017 | $866,989 |
| | 2017 | 2017 | CURZA GLOBAL LLC | 5152 EDGEWOOD DR STE 375 | PROVO | UT | 84604-5596 | UTAH | USA | R43AI124821 | Natural product-inspired antibacterials with unique ribosomal binding | 000 | 2 | NIH | 6/28/2017 | $298,770 |
| | 2017 | 2017 | CURZA GLOBAL LLC | 5152 EDGEWOOD DR STE 375 | PROVO | UT | 84604-5596 | UTAH | USA | R43AI124821 | Natural product-inspired antibacterials with unique ribosomal binding | 001 | 2 | NIH | 8/25/2017 | $298,770 |
|
| Issue Date FY: 2016 ( Subtotal = $300,000 ) |
| | 2016 | 2016 | CURZA GLOBAL LLC | 5152 EDGEWOOD DR STE 375 | PROVO | UT | 846045596-5596 | UTAH | USA | R43AI124821 | Natural product-inspired antibacterials with unique ribosomal binding | 001 | 1 | NIH | 6/28/2016 | -$300,000 |
| | 2016 | 2016 | CURZA GLOBAL LLC | 5152 EDGEWOOD DR STE 375 | PROVO | UT | 84604-5596 | UTAH | USA | R43AI124821 | Natural product-inspired antibacterials with unique ribosomal binding | 000 | 1 | NIH | 6/22/2016 | $300,000 |
| | 2016 | 2016 | CURZA GLOBAL LLC | 5152 EDGEWOOD DR STE 375 | PROVO | UT | 846045596-5596 | UTAH | USA | R43AI124821 | Natural product-inspired antibacterials with unique ribosomal binding | 001 | 1 | NIH | 6/28/2016 | $300,000 |
|
|
